News
Article
Author(s):
Dermatology Times is recapping our exclusive expert interviews from the month of June.
Ben Lockshin, MD, FAAD, covered ways in which GLP-1 RAs can be utilized when treating psoriatic disease.
Explore more insights from key opinion leaders in exclusive Q&As and written articles:
Discover the latest advancements in aesthetics as Heather Gates, PA-C, shares innovative techniques and emerging technologies from this groundbreaking workshop.
Tristan Hasbargen, PA-C, led a hands-on suturing workshop at the Fall Clinical NP/PA Conference, enhancing skills in surgical dermatology.
Discover innovative strategies for AK treatment from Darrell Rigel, MD, MS, at the latest Fall Clinical PA/NP conference.
Friedman discusses survey findings revealing inconsistent screening, outdated assumptions, and lack of FDA-approved therapies for lichen planus.
At RAD 2025, Jonathan Silverberg, MD, PhD, MPH, provided an in-depth look at the clinical integration of newly approved biologics nemolizumab and lebrikizumab in AD.
At RAD 2025, Tiffany Mayo, MD, emphasized the need for clinicians to recognize shared inflammatory mechanisms between AD and AA.
At RAD 2025, pediatric dermatologist Lisa Swanson, MD, and allergist Anne Marie Singh, MD, led a dual session aimed at demystifying the connection between food allergy and atopic dermatitis.
At the 2025 Revolutionizing Atopic Dermatitis Conference, Gil Yosipovitch, MD, explored the pathophysiology of chronic itch through the lens of type 2 cytokine inhibition, neuromodulatory therapies, and more.
At the 2025 Revolutionizing Atopic Dermatitis Conference, JiaDe “Jeff” Yu, MD, MS, discussed the multifactorial nature of chronic hand eczema, highlighting its distinction from atopic dermatitis.
At RAD 2025, Brad Glick, DO, MPH, reviewed the clinical signs of topical steroid withdrawal, the need for detailed patient histories to distinguish it from severe AD flares, and the role of targeted non-steroidal and systemic therapies.
At RAD 2025, Christopher Bunick, MD, PhD, presented data on amlitelimab and rocatinlimab, highlighting their potential to suppress cytokine signaling and more.
At RAD 2025, Matthew Zirwas, MD, explored the distinct clinical profiles of IL-31 and IL-13 inhibitors, highlighting nemolizumab’s potential superiority for itch relief.
Maureen Offiah, MD, reflected on the key takeaways as an attendee at the 2025 Revolutionizing Atopic Dermatitis (RAD) Conference in Nashville, Tennessee.
Mercedes Gonzalez, MD, discusses the promising INTEGUMENT-INFANT trial, exploring a new non-steroidal treatment for infants with atopic dermatitis.
At SCALE 2025, Christina Feser, DO, FAAD, FAOCD, spotlighted the rapidly expanding pipeline of diverse therapies for patients with HS.
Iris Rubin, MD, reveals how her brand SEEN transforms hair products to combat acne, promoting clearer skin through innovative, skin-friendly formulations.
Don’t miss a moment of Dermatology Times by signing up for our eNewsletters and subscribing to receive the free print issue and supplements each month.
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
